

Clinical Trails registered on ClinicalTrials.gov - Accessed 27th January, 2017

| Rank | Status                 | Study   |
|------|------------------------|---|
| 1    | Unknown                | <a href="#">Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer</a>  |
|      |                        | <b>Condition:</b> Hepatocellular Cancer<br><b>Interventions:</b> Drug: Sorafenib; Radiation: yttrium-90 radioembolization   |
| 2    | Recruiting             | <a href="#">Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study</a>   |
|      |                        | <b>Condition:</b> Neuroendocrine Tumors<br><b>Intervention:</b> Device: Holmium-166 microspheres hepatic radioembolization.   |
| 3    | Active, not recruiting | <a href="#">Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases</a>  |
|      |                        | <b>Condition:</b> Neuroendocrine Tumors<br><b>Interventions:</b> Drug: Pasireotide; Procedure: Sir-sphere Radioembolization; Drug: Everolimus   |
| 4    | Recruiting             | <a href="#">Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma</a>  |
|      |                        | <b>Condition:</b> Hepatocellular Carcinoma<br><b>Interventions:</b> Procedure: Transarterial Radioembolization; Procedure: Transarterial Chemoembolization using drug-eluting beads   |
| 5    | Recruiting             | <a href="#">Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma</a>   |
|      |                        | <b>Condition:</b> HepatoCellular Carcinoma<br><b>Interventions:</b> Radiation: Y-90 Radioembolization; Drug: Nivolumab  |
| 6    | Recruiting             | <a href="#">Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases</a>  |
|      |                        | <b>Conditions:</b> Colon Cancer; Rectal Cancer; Liver Metastases<br><b>Interventions:</b> Drug: Tas-102; Device: SIR-Sphere   |
| 7    | Recruiting             | <a href="#">Feasibility of Single Session In-Room Yttrium-90 Radioembolization Diagnostic Angiography and Treatment</a>   |
|      |                        | <b>Conditions:</b> Malignant Neoplasms of Digestive Organs; Metastatic Liver Tumors<br><b>Intervention:</b> Device: SIR-Spheres   |
| 8    | Recruiting             | <a href="#">Local Ablative Strategies After Endovascular Radioembolization (LASER)</a>  |
|      |                        | <b>Condition:</b> Metastatic Colorectal Cancer<br><b>Interventions:</b> Device: PET/MRI; Radiation: Percutaneous microwave ablation; Radiation: Stereotactic body radiotherapy  |
| 9    | Recruiting             | <a href="#">Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma</a>   |
|      |                        | <b>Condition:</b> Ocular Melanoma<br><b>Interventions:</b> Drug: Sorafenib; Device: Radioembolization with SIR-Spheres® (Yttrium Microspheres)  |
| 10   | Active, not recruiting | <a href="#">PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer</a>   |
|      |                        | <b>Conditions:</b> Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Metastatic Extrahepatic Bile Duct Cancer; Recurrent Adult Primary Liver Cancer; Recurrent Extrahepatic Bile Duct Cancer; Stage D Adult Primary Liver Cancer (BCLC); Unspecified Adult Solid Tumor, Protocol Specific<br><b>Interventions:</b> Procedure: PET scan; Procedure: CT Scan; Procedure: hepatic artery embolization |
| 11   | Unknown †              | <a href="#">Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project</a>  |
|      |                        | <b>Conditions:</b> Colorectal Cancer; Liver Metastases<br><b>Intervention:</b>  |
| 12   | Recruiting             | <a href="#">Transarterial Radioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)</a>  |
|      |                        | <b>Condition:</b> Hepatocellular Carcinoma<br><b>Interventions:</b> Drug: TACE-DEB; Drug: 90Y-RE  |
| 13   | Recruiting             | <a href="#">Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization</a>  |
|      |                        | <b>Conditions:</b> Colorectal Neoplasms; Neoplasm Metastasis; Liver Diseases; Digestive System Neoplasms<br><b>Intervention:</b> Device: Holmium-166-poly (L-lactic acid) microspheres  |
| 14   | Recruiting             | <a href="#">Microsphere Localization Using Image Result for Positron Emission Tomography-Magnetic Resonance Imaging (PET/MRI) or Positron Emission Tomography-Computed Tomography (PET/CT) in Patients With Liver Disease</a>   |
|      |                        | <b>Condition:</b> Liver Neoplasms<br><b>Interventions:</b> Device: PET/MR; Device: PET/CT   |
| 15   | Not yet recruiting     | <a href="#">Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres</a>   |
|      |                        | <b>Conditions:</b> Neuroendocrine Tumors; Gastrointestinal Neoplasms; Carcinoid Tumors<br><b>Interventions:</b> Drug: Lanreotide; Device: Y-90 microspheres   |

|    |                        |  |  |
|----|------------------------|--|--|
| 16 | Recruiting             | <a href="#">Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases</a> |  |
|    |                        | <b>Condition:</b>  | Colorectal Neoplasms   |
| 17 | Active, not recruiting | <a href="#">Pair Production PET Imaging to Detect Particle Distribution in Patients Undergoing Yttrium-90 Radioembolization</a>  |  |
|    |                        | <b>Condition:</b>  | Carcinoma, Hepatocellular  |
| 18 | Recruiting             | <a href="#">Prospective Post Y90 Liver Hypertrophy</a>   |  |
|    |                        | <b>Intervention:</b>   | Other: CT volumetric measurement after Y90 radioembolization   |
| 19 | Active, not recruiting | <a href="#">Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT</a>  |  |
|    |                        | <b>Interventions:</b>  | Procedure: positron emission tomography;<br>Procedure: computed tomography   |
| 20 | Recruiting             | <a href="#">Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis</a>  |  |
|    |                        | <b>Interventions:</b>  | Procedure: SIRT; Procedure: DSM-TACE   |
| 21 | Recruiting             | <a href="#">Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry</a>   |  |
|    |                        | <b>Interventions:</b>  | Radiation: CT Liver Perfusion; Radiation: PET/CT of liver  |
| 22 | Recruiting             | <a href="#">Interest of Functional MRI (Magnetic Resonance Imagery) (in Patients Suffering From Hepatocellular Carcinoma and Treated With Yttrium</a>                      |  |
|    |                        | <b>Intervention:</b>   | Other: Additional RMIs   |
| 23 | Active, not recruiting | <a href="#">Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver</a>   |  |
|    |                        | <b>Interventions:</b>  | Procedure: RFA; Procedure: Radioembolization (SIRT)  |
| 24 | Recruiting             | <a href="#">CIRSE Registry for SIR-Spheres Therapy</a>   |  |
|    |                        | <b>Interventions:</b>  | Device: Yttrium-90 loaded SIR-Spheres microspheres;<br>Behavioral: QLQ-C30 with HCC module   |
| 25 | Recruiting             | <a href="#">90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma</a>                                  |  |
|    |                        | <b>Interventions:</b>  | Device: SIR-Spheres microspheres (Yttrium-90 Microspheres);<br>Drug: Gemcitabine; Drug: Cisplatin  |
| 26 | Recruiting             | <a href="#">Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer</a>  |  |
|    |                        | <b>Interventions:</b>  | Device: HAI-90Y radioembolization (SIR-spheres injection);<br>Drug: systemic chemotherapy LV5FU2   |
| 27 | Recruiting             | <a href="#">Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma</a>   |  |
|    |                        | <b>Intervention:</b>   |  |
| 28 | Not yet recruiting     | <a href="#">Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver</a>                                      |  |
|    |                        | <b>Interventions:</b>  | Biological: Durvalumab; Other: Laboratory Biomarker Analysis;<br>Biological: Tremelimumab  |
| 29 | Recruiting             | <a href="#">Definitive Therapy for Oligometastatic Solid Malignancies</a>  |  |
|    |                        | <b>Interventions:</b>  | Procedure: Complete Surgical Removal;<br>Radiation: Stereotactic Radiosurgery;<br>Radiation: Ablative external beam radiation dose; Procedure: Subtotal surgical removal plus ablative radiation dose;<br>Radiation: Radioembolization |
| 30 | Active, not recruiting | <a href="#">Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma</a>                    |  |
|    |                        | <b>Intervention:</b>   | Radiation: Therasphere® in association with Gemcitabine and Cisplatin  |
| 31 | Recruiting             | <a href="#">Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus Standard Dosimetry</a>                                   |  |
|    |                        | <b>Interventions:</b>  | Radiation: Optimized Internal Radiation Therapy;<br>Radiation: Standard Internal Radiation Therapy   |

|    |                        |   |
|----|------------------------|---|
| 32 | Unknown                | <a href="#">Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).</a>                        |
|    |                        | <b>Condition:</b> Intrahepatic Cholangiocellular Carcinoma<br><b>Interventions:</b> Procedure: DEB TACE; Procedure: SIRT  |
| 33 | Unknown                | <a href="#">PERfusion CT in the FOXFIRE Trial to Study Blood Flow to Liver Metastases</a>   |
|    |                        | <b>Condition:</b> Metastatic Colorectal Cancer<br><b>Intervention:</b> Other: Perfusion CT scan   |
| 34 | Recruiting             | <a href="#">Prospective Tumor Response Evaluation</a>   |
|    |                        | <b>Conditions:</b> Hepatocellular Cancer; Metastatic Liver Cancer<br><b>Interventions:</b> Procedure: TACE; Procedure: Y-90; Procedure: MWA; Procedure: IRE                         |
| 35 | Recruiting             | <a href="#">Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma</a>  |
|    |                        | <b>Condition:</b> Hepatocellular Carcinoma<br><b>Interventions:</b> Procedure: Transarterial Radioembolization; Procedure: Transarterial Chemoembolization using drug-eluting beads |
| 36 | Unknown                | <a href="#">Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer</a>  |
|    |                        | <b>Condition:</b> Hepatocellular Cancer<br><b>Interventions:</b> Drug: Sorafenib; Radiation: yttrium-90 radioembolization   |
| 37 | Recruiting             | <a href="#">Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma (HCC)</a>  |
|    |                        | <b>Condition:</b> Hepatocellular Carcinoma<br><b>Interventions:</b> Drug: TACE-DEB; Drug: 90Y-RE  |
| 38 | Recruiting             | <a href="#">90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma</a>   |
|    |                        | <b>Condition:</b> Intrahepatic Cholangiocarcinoma<br><b>Interventions:</b> Device: SIR-Spheres microspheres (Yttrium-90 Microspheres); Drug: Gemcitabine; Drug: Cisplatin           |
| 39 | Recruiting             | <a href="#">Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis</a>   |
|    |                        | <b>Condition:</b> Uveal Melanoma<br><b>Interventions:</b> Procedure: SIRT; Procedure: DSM-TACE  |
| 40 | Unknown                | <a href="#">Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).</a>                        |
|    |                        | <b>Condition:</b> Intrahepatic Cholangiocellular Carcinoma<br><b>Interventions:</b> Procedure: DEB TACE; Procedure: SIRT  |
| 41 | Recruiting             | <a href="#">90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma</a>   |
|    |                        | <b>Condition:</b> Intrahepatic Cholangiocarcinoma<br><b>Interventions:</b> Device: SIR-Spheres microspheres (Yttrium-90 Microspheres); Drug: Gemcitabine; Drug: Cisplatin           |
| 42 | Recruiting             | <a href="#">11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE</a>   |
|    |                        | <b>Condition:</b> Hepatocarcinoma<br><b>Intervention:</b> Other: No intervention  |
| 43 | Recruiting             | <a href="#">Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma</a>  |
|    |                        | <b>Condition:</b> Hepatocellular Carcinoma<br><b>Interventions:</b> Procedure: Transarterial Radioembolization; Procedure: Transarterial Chemoembolization using drug-eluting beads |
| 44 | Unknown                | <a href="#">Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer</a>  |
|    |                        | <b>Condition:</b> Hepatocellular Cancer<br><b>Interventions:</b> Drug: Sorafenib; Radiation: yttrium-90 radioembolization   |
| 45 | Recruiting             | <a href="#">Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry</a>  |
|    |                        | <b>Condition:</b> Hepatocellular Carcinoma<br><b>Interventions:</b> Radiation: CT Liver Perfusion; Radiation: PET/CT of liver   |
| 46 | Unknown                | <a href="#">Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment</a>  |
|    |                        | <b>Condition:</b> Intrahepatic Cholangiocellular Carcinoma<br><b>Interventions:</b> Procedure: DEB TACE; Procedure: SIRT  |
| 47 | Recruiting             | <a href="#">Treatment for Bile Duct Cancer in the Liver</a>   |
|    |                        | <b>Condition:</b> Cholangio Carcinoma<br><b>Intervention:</b> Drug: SIRT Yttrium-90   |
| 48 | Active, not recruiting | <a href="#">Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced</a>   |
|    |                        | <b>Condition:</b> Hepatocellular Carcinoma<br><b>Interventions:</b> Device: SIR-Spheres; Drug: Sorafenib tosylate   |
| 49 | Recruiting             | <a href="#">Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus</a>   |
|    |                        | <b>Condition:</b> Adenoma, Liver Cell<br><b>Interventions:</b> Radiation: Optimized Internal Radiation Therapy; Radiation: Standard Internal Radiation Therapy                      |
| 50 | Active, not recruiting | <a href="#">CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases</a>   |
|    |                        | <b>Condition:</b> Liver Metastases<br><b>Interventions:</b> Biological: anti-CEA CAR-T cells; Device: Sir-Spheres   |

|    |                        |   |   |
|----|------------------------|---|---|
| 51 | Not yet recruiting     | <a href="#">SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of</a>  | <b>Condition:</b> Intrahepatic Cholangiocarcinoma   |
|    |                        | <b>Interventions:</b> Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)   |   |
| 52 | Recruiting             | <a href="#">Prospective Post Y90 Liver Hypertrophy</a>  | <b>Conditions:</b> Hepatocellular Carcinoma; Liver Hypertrophy  |
|    |                        | <b>Intervention:</b> Other: CT volumetric measurement after Y90 radioembolization   |   |
| 53 | Recruiting             | <a href="#">CIRSE Registry for SIR-Spheres Therapy</a>  | <b>Condition:</b> Liver Carcinoma   |
|    |                        | <b>Interventions:</b> Device: Yttrium-90 loaded SIR-Spheres microspheres; Behavioral: QLQ-C30 with HCC module   |   |
| 54 | Recruiting             | <a href="#">Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma</a>   | <b>Condition:</b> HepatoCellular Carcinoma  |
|    |                        | <b>Interventions:</b> Radiation: Y-90 Radioembolization; Drug: Nivolumab  |   |
| 55 | Active, not recruiting | <a href="#">FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary</a>   | <b>Condition:</b> Colorectal Cancer Metastatic  |
|    |                        | <b>Interventions:</b> Drug: FOLFOX6m; Device: SIR-Spheres microspheres  |   |
| 56 | Unknown                | <a href="#">Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and</a>   | <b>Conditions:</b> Metastatic Cancer; Pancreatic Cancer   |
|    |                        | <b>Interventions:</b> Drug: fluorouracil; Radiation: selective external radiation therapy; Radiation: tomotherapy; Radiation: yttrium Y 90 glass microspheres; Radiation: yttrium Y 90 resin microspheres |   |
| 57 | Not yet recruiting     | <a href="#">Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are</a>  | <b>Conditions:</b> Neuroendocrine Tumors; Gastrointestinal Neoplasms; Carcinoid Tumors  |
|    |                        | <b>Interventions:</b> Drug: Lanreotide; Device: Y-90 microspheres   |   |
| 58 | Recruiting             | <a href="#">SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver</a>   | <b>Condition:</b> Stage IV Uveal Melanoma   |
|    |                        | <b>Intervention:</b> Device: Sir-Spheres®   |   |
| 59 | Active, not recruiting | <a href="#">Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT</a>   | <b>Conditions:</b> Advanced Adult Primary Liver Cancer; Liver Metastases; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer |
|    |                        | <b>Interventions:</b> Procedure: positron emission tomography; Procedure: computed tomography   |   |
| 60 | Active, not recruiting | <a href="#">Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein</a>  | <b>Condition:</b> Hepatocellular Carcinoma  |
|    |                        | <b>Interventions:</b> Device: TheraSphere; Drug: Sorafenib  |   |
| 61 | Active, not recruiting | <a href="#">Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or</a>  | <b>Conditions:</b> Liver Cancer; Metastatic Cancer  |
|    |                        | <b>Interventions:</b> Drug: capecitabine; Radiation: yttrium Y 90 glass microspheres  |   |
| 62 | Recruiting             | <a href="#">Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma</a>  | <b>Condition:</b> Liver Neoplasms   |
|    |                        | <b>Intervention:</b>  |   |
| 63 | Active, not recruiting | <a href="#">Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced</a>   | <b>Condition:</b> Hepatocellular Carcinoma  |
|    |                        | <b>Interventions:</b> Device: SIR-Spheres; Drug: Sorafenib tosylate   |   |
| 64 | Recruiting             | <a href="#">Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma</a>  | <b>Condition:</b> Uveal Melanoma  |
|    |                        | <b>Interventions:</b> Procedure: SIRT; Procedure: DSM-TACE  |   |
| 65 | Recruiting             | <a href="#">Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC)</a>   | <b>Condition:</b> Liver Cancer  |
|    |                        | <b>Interventions:</b> Drug: Sorafenib; Radiation: Yttrium-90 Microspheres; Behavioral: Follow-Up Phone Calls  |   |
| 66 | Active, not recruiting | <a href="#">CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases</a>   | <b>Condition:</b> Liver Metastases  |
|    |                        | <b>Interventions:</b> Biological: anti-CEA CAR-T cells; Device: Sir-Spheres   |   |
| 67 | Active, not recruiting | <a href="#">FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary</a>   | <b>Conditions:</b> Colorectal Cancer; Colorectal Carcinoma; Liver Metastases  |
|    |                        | <b>Interventions:</b> Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres   |   |
| 68 | Recruiting             | <a href="#">Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer</a>   | <b>Condition:</b> Unresectable Hepatocellular Carcinoma   |
|    |                        | <b>Intervention:</b> Device: TheraSphere  |   |
| 69 | Recruiting             | <a href="#">Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal</a>  | <b>Condition:</b> Colorectal Cancer Metastatic  |
|    |                        | <b>Intervention:</b> Device: TheraSphere  |   |
| 70 | Unknown                | <a href="#">Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be</a>   | <b>Condition:</b> Liver Cancer  |
|    |                        | <b>Intervention:</b> Radiation: yttrium Y 90 glass microspheres   |   |
| 71 | Recruiting             | <a href="#">90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic</a>  | <b>Condition:</b> Intrahepatic Cholangiocarcinoma   |
|    |                        | <b>Interventions:</b> Device: SIR-Spheres microspheres (Yttrium-90 Microspheres); Drug: Gemcitabine; Drug: Cisplatin  |   |

|     |                         |   |   |
|-----|-------------------------|---|---|
| 72  | Recruiting              | <a href="#">Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus</a> |   |
|     |                         | <b>Condition:</b>   | Adenoma, Liver Cell   |
| 73  | Recruiting              | <a href="#">Transarterial Radioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular</a>          |   |
|     |                         | <b>Condition:</b>   | Hepatocellular Carcinoma  |
| 74  | Recruiting              | <a href="#">Yttrium90, Ipilimumab, &amp; Nivolumab for Uveal Melanoma With Liver Metastases</a>                       |   |
|     |                         | <b>Interventions:</b>   | Drug: TACE-DEB; Drug: 90Y-RE  |
| 75  | Recruiting              | <a href="#">Yttrium90, Ipilimumab, &amp; Nivolumab for Uveal Melanoma With Liver Metastases</a>                       |   |
|     |                         | <b>Conditions:</b>  | Uveal Melanoma; Hepatic Metastases  |
| 76  | Recruiting              | <a href="#">Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver</a>       |   |
|     |                         | <b>Interventions:</b>   | Device: SIR-Spheres® Yttrium 90; Drug: ipilimumab; Drug: nivolumab  |
| 77  | Recruiting              | <a href="#">Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver</a>       |   |
|     |                         | <b>Conditions:</b>  | Colon Cancer; Rectal Cancer; Liver Metastases   |
| 78  | Unknown                 | <a href="#">Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study</a>         |   |
|     |                         | <b>Intervention:</b>  | Other: Yttrium-90 Resin Microspheres  |
| 79  | Recruiting              | <a href="#">Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer</a>         |   |
|     |                         | <b>Conditions:</b>  | Stage IIIA Hepatocellular Carcinoma; Stage IIIB Hepatocellular Carcinoma; Stage IIIC Hepatocellular Carcinoma; Stage IVA Hepatocellular Carcinoma; Stage IVB Hepatocellular Carcinoma |
| 80  | Unknown                 | <a href="#">Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization</a>  |   |
|     |                         | <b>Intervention:</b>  | Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Radiation: Yttrium Y 90 Glass Microspheres   |
| 81  | Recruiting              | <a href="#">Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal</a>        |   |
|     |                         | <b>Condition:</b>   | Colorectal Cancer   |
| 82  | Active, not recruiting  | <a href="#">Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With</a>          |   |
|     |                         | <b>Interventions:</b>   | Device: HAI-90Y radioembolization (SIR-spheres injection); Drug: systemic chemotherapy LV5FU2   |
| 83  | Unknown                 | <a href="#">Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced</a>        |   |
|     |                         | <b>Condition:</b>   | Colorectal Neoplasms  |
| 84  | Recruiting              | <a href="#">Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous</a>        |   |
|     |                         | <b>Intervention:</b>  | Device: SIR-Spheres; Drug: Regorafenib  |
| 85  | Recruiting              | <a href="#">Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery</a>     |   |
|     |                         | <b>Conditions:</b>  | Hepatocellular Cancer   |
| 86  | Not yet recruiting      | <a href="#">SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of</a>      |   |
|     |                         | <b>Interventions:</b>   | Drug: Sorafenib; Radiation: yttrium-90 radioembolization  |
| 87  | Recruiting              | <a href="#">Microsphere Localization Using Image Result for Positron Emission Tomography-Magnetic Resonance</a>       |   |
|     |                         | <b>Condition:</b>   | Cholangiocarcinoma  |
| 88  | Recruiting              | <a href="#">Treatment for Bile Duct Cancer in the Liver</a>   |   |
|     |                         | <b>Intervention:</b>  | Radiation: Therasphere® in association with Gemcitabine and Cisplatin   |
| 89  | Unknown                 | <a href="#">Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors</a>                             |   |
|     |                         | <b>Conditions:</b>  | Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer                  |
| 90  | Unknown                 | <a href="#">Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and</a>   |   |
|     |                         | <b>Interventions:</b>   | Radiation: yttrium Y 90 glass microspheres; Other: laboratory biomarker analysis  |
| 91  | Enrolling by invitation | <a href="#">Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an</a>  |   |
|     |                         | <b>Condition:</b>   | Intrahepatic Cholangiocarcinoma   |
| 92  | Recruiting              | <a href="#">Humanitarian Device Exemption (HDE) Treatment Protocol For Treatment of Unresectable Hepatocellular</a>   |   |
|     |                         | <b>Interventions:</b>   | Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)   |
| 93  | Recruiting              | <a href="#">Microsphere Localization Using Image Result for Positron Emission Tomography-Magnetic Resonance</a>       |   |
|     |                         | <b>Condition:</b>   | Liver Neoplasms   |
| 94  | Recruiting              | <a href="#">Treatment for Bile Duct Cancer in the Liver</a>   |   |
|     |                         | <b>Interventions:</b>   | Device: PET/MR; Device: PET/CT  |
| 95  | Unknown                 | <a href="#">Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors</a>                             |   |
|     |                         | <b>Condition:</b>   | Cholangio Carcinoma   |
| 96  | Unknown                 | <a href="#">Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and</a>   |   |
|     |                         | <b>Intervention:</b>  | Drug: SIRT Yttrium-90   |
| 97  | Unknown                 | <a href="#">Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and</a>   |   |
|     |                         | <b>Conditions:</b>  | Metastatic Cancer; Pancreatic Cancer  |
| 98  | Enrolling by invitation | <a href="#">Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an</a>  |   |
|     |                         | <b>Interventions:</b>   | Drug: fluorouracil; Radiation: selective external radiation therapy; Radiation: tomotherapy; Radiation: yttrium Y 90 glass microspheres; Radiation: yttrium Y 90 resin microspheres   |
| 99  | Recruiting              | <a href="#">Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an</a>  |   |
|     |                         | <b>Conditions:</b>  | Liver Cancer; Hepatoma  |
| 100 | Recruiting              | <a href="#">Humanitarian Device Exemption (HDE) Treatment Protocol For Treatment of Unresectable Hepatocellular</a>   |   |
|     |                         | <b>Intervention:</b>  | Device: Yttrium 90 (TheraSphere)  |
| 101 | Recruiting              | <a href="#">Humanitarian Device Exemption (HDE) Treatment Protocol For Treatment of Unresectable Hepatocellular</a>   |   |
|     |                         | <b>Conditions:</b>  | Carcinoma, Hepatocellular; Liver Cancer   |
| 102 | Recruiting              | <a href="#">Humanitarian Device Exemption (HDE) Treatment Protocol For Treatment of Unresectable Hepatocellular</a>   |   |
|     |                         | <b>Intervention:</b>  | Device: TheraSphere Treatment   |

|    |            |   |
|----|------------|---|
| 91 | Recruiting | <a href="#">Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by</a>  |
|    |            | <b>Conditions:</b> Liver Cancer; Metastatic Cancer<br><b>Intervention:</b> Radiation: Yttrium Y 90 glass microspheres   |
| 92 | Recruiting | <a href="#">Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery</a>   |
|    |            | <b>Condition:</b> Liver Cancer<br><b>Intervention:</b> Radiation: yttrium Y 90 glass microspheres   |
| 93 | Unknown    | <a href="#">Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the</a>  |
|    |            | <b>Conditions:</b> Colorectal Cancer; Metastatic Cancer<br><b>Interventions:</b> Drug: floxuridine; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin |
| 94 | Recruiting | <a href="#">Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular</a>  |
|    |            | <b>Condition:</b> Hepatocellular Carcinoma<br><b>Interventions:</b> Procedure: Transarterial Radioembolization; Procedure: Transarterial Chemoembolization using drug-eluting beads                 |